Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alrizomadlin - Ascentage Pharma

Next Previous
Drug Profile

Alrizomadlin - Ascentage Pharma

Alternative Names: APG-115

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentage Pharma
  • Developer Ascentage Pharma; Suzhou Yasheng Pharmaceutical; University of Michigan
  • Class Amides; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Retinoblastoma; Gastric cancer; Acute myeloid leukaemia; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Solid tumours; T-cell prolymphocytic leukaemia
  • Phase I/II Acute myeloid leukaemia; Liposarcoma; Salivary gland cancer
  • Phase I Myelodysplastic syndromes; Neuroblastoma
  • Preclinical Dry age-related macular degeneration; Multiple myeloma; Uveal melanoma
  • No development reported Gastric cancer; Lymphoma

Most Recent Events

  • 07 Apr 2024 Pharmacodynamics data from a preclinical trial in Prostate cancer released by Ascentage Pharma
  • 05 Mar 2024 Pharmacodynamics data from a preclinical study in Prostate cancer released by Ascentage Pharma
  • 01 Mar 2024 Ascentage Pharma Group terminates a phase-I/II trial in Salivary gland cancer (Second-line therapy or greater, Combination therapy, Monotherapy) in USA (PO) as enrollment has been placed on hold due to pending evaluability assessment (NCT03781986)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top